UNSPSC 51123119: Tocainide hydrochloride

This classification denotes a cation channel blocker and antiarrhythmic agent with the molecular formula C11H16N2O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2K7I38CKN5, chemically known as 2-amino-n-(2,6-dimethylphenyl)propanamide monohydrochloride but more generally known as tocainide hydrochloride, which bears US NIH Compound Identifier 108173. European Medicines Agency schedules Tocainide hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04897MIG.

UNSPSC 51123119 Tocainide hydrochloride is a Commodity code representing specific pharmaceutical active ingredients procured by state and local health systems, fire rescue services, and multistate cooperative purchasing alliances. State and local governments use this code to procure emergency medications and generic pharmaceuticals for emergency medical services, hospital formularies, and public health programs. Issuing bodies include municipal fire departments, state health and human services commissions, and regional cooperative purchasing organizations that aggregate demand across multiple member jurisdictions. The City of Tampa Purchasing Department, the Texas Health and Human Services Commission, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) are active recent buyers under related pharmaceutical procurement activity. Work solicited ranges from single-medication line-item supply contracts serving emergency response teams to broad generic pharmaceutical portfolios distributed through authorized wholesalers across multiple states.

Geographic activity centers on Florida, Texas, and Minnesota based on recent solicitations. The City of Tampa issued an IFB (Solicitation 26P00188) on April 24, 2026, for Advanced Life Support Medications including epinephrine, labetalol, adenosine, and diltiazem to supply Tampa Fire Rescue with a contract value of $40,000 and a response deadline of April 8, 2026, featuring a 5 percent Small Local Business Enterprise bid discount. The Minnesota Department of Administration's MMCAP issued an RFP (S1070000015802) posted January 20, 2026, with a March 26, 2026, response deadline to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across state and local government facilities in Minnesota and Oregon, requiring vendor compliance with cGMP, DSCSA, and pricing through three authorized wholesalers. The Texas Health and Human Services Commission issued an exploratory RFI (HHS0017013) in late March 2026 regarding direct-to-manufacturer prescription programs, signaling early-stage procurement development rather than immediate award opportunity. Recent state and local activity emphasizes firm pricing, nine-month minimum shelf life, compliance with federal accessibility and OSHA standards, and compatibility with established wholesale distribution channels.